Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0226

Congress meeting · Dr. Emiko Quinn

05 Aug 2026 · Phone · Dr. Emiko Quinn, A.C. Camargo Cancer Center · MSL Luis Ortega · Lumeva

ReviewedManualENG-0226—

Capture insight from this engagement

Location: A.C. Camargo Cancer Center
Therapeutic area: Neurology
Country: Brazil
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Chronic migraine data
Switching between CGRP agents

Scientific content used

LMV persistence data summary
Chronic migraine scientific platform

Questions raised

No questions recorded.

Notes

Congress meeting with general neurologist at A.C. Camargo Cancer Center. Discussed chronic migraine data, switching between cgrp agents.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 3
Depth of exchange: 3
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0226

Audit history (0)

All create, update and approval events for this record

No audit events in sample data